文献速递淋巴瘤

恶病质是接受嵌合抗原受体T细胞治疗的B细胞非霍奇金淋巴瘤患者临床和功能不良结局的危险因素

Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
PubMed 文献 · Br J Haematol · 2022-02-09

该研究在接受了嵌合抗原受体T细胞(CAR-T)治疗的侵袭性B细胞非霍奇金淋巴瘤患者中,探讨了恶病质标志物与肿瘤及功能结局的关系。研究发现预后营养指数与无进展生存期、总生存期和无残疾生存期相关,其他基于体重和血清的恶病质标志物也与不良结局相关。

要点

  • 预后营养指数与接受CAR-T治疗患者的无进展生存期、总生存期和无残疾生存期相关。
  • 其他基于体重和血清的恶病质标志物也与不良结局相关。
  • 这些数据提示需在接受CAR-T细胞治疗的人群中进一步研究恶病质标志物。

核心结论

  • 恶病质标志物与接受CAR-T治疗的侵袭性B细胞非霍奇金淋巴瘤患者的不良临床和功能结局相关。
  • 这些数据提示需在接受CAR-T细胞治疗的人群中进一步研究恶病质标志物。

研究设计与样本

  • 在接受了CAR-T治疗的侵袭性B细胞非霍奇金淋巴瘤患者中开展的一项先导性(pilot)研究,分析了恶病质标志物与肿瘤及功能结局之间的关系。

主要发现

  • 预后营养指数与无进展生存期、总生存期和无残疾生存期相关。
  • 其他基于体重和血清的恶病质标志物也与不良结局相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cachexia is a muscle-wasting syndrome that is known to impact the clinical course of several cancer populations but has not been specifically investigated in patients receiving chimeric antigen receptor T (CAR-T) cell therapy. In this study, we investigated the relationship between cachexia markers and several cancer and functional outcomes in a pilot population of aggressive B-cell non-Hodgkin lymphoma patients receiving CAR-T. We found that the prognostic nutritional index was linked to progression-free survival, overall survival, and disability-free survival, while several additional weight and serum-based markers of cachexia were also associated with negative outcomes. These data prompt further investigation of cachexia markers in populations receiving CAR-T cell therapy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Roy I, Smilnak G, Burkart M, et al. Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Br J Haematol. 2022. PMID: 35141891. doi:10.1111/bjh.18054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。